Glucuronide Metabolites, Why Bother?
Join one of our webinars on “Glucuronide Metabolites, Why Bother?” on Wednesday July 1st or Thursday July 2nd 2020 to learn about the need for accessing glucuronides during drug discovery projects.
Evolution of drug design strategies away from single CYP mediated mechanisms towards more metabolically stable drugs has resulted in an increase in clearance by other mechanisms such as glucuronidation. Metabolism of drugs by UDP-glucuronosyltransferases (UGTs) is the most important phase II route of metabolism resulting in the formation of 0-, N– and acyl glucuronides. In this 40-minute webinar, we will explore the need and routes to accessing different types of glucuronides, illustrated using case studies from the literature as well as recent examples from projects undertaken for Hypha’s clients.
Register for one of the webinars via the links below:
Wednesday 1st July
Webinar 1 1pm BST / 2pm CEST / 8am Eastern time
Webinar 2 5pm BST / 12 noon Eastern time / 9am Pacific time
Thursday 2nd July
Webinar 3 1pm BST / 2pm CEST / 8am Eastern time
Webinar 4 5pm BST / 12 noon Eastern time / 9am Pacific time
One-Stop Metabolite Shop
If you missed our webinar on our One-stop Metabolite Shop: “New tools for metabolite synthesis: enhanced PolyCYPs+ kit and late-stage chemical glucuronidation“, but are interested in learning more, please contact us for a link to a recording.
In the webinar our CEO Dr Liam Evans shared Hypha’s new one-stop shop for metabolite synthesis, including our enhanced PolyCYPs®+ screening kits and a new late-stage chemical glucuronidation screen.
The chemical screen is suitable for synthesis of O-, N- and acyl glucuronides and features tailored deprotection strategies suitable for synthesis of acyl glucuronides and some unstable N-glucuronides. The chemical screen is complementary to our existing successful microbial and mammalian biotransformation routes for generating phase II conjugates.
The extended PolyCYPs®+ kits comprise 18 diverse CYP isoforms cloned from some of Hypha’s bacteria, as well as complimentary inclusion of two other phase 1 enzymes – human aldehyde oxidase (AOX1) and flavin monooxygenase 3 (FMO3), with other FMO isoforms to be incorporated as they become available.